使用伦瓦替尼布有效治疗具有广泛腹腔扩散的晚期肝细胞癌
Shinya Wakatsuki1, Shinya Sakamoto2, Akiko Ueno1
1Department of Obstetrics and Gynecology, Kochi Health Sciences Center.
Acta medica Okayama
|February 26, 2026
概括
伦瓦提尼布在稳定高级肝细胞癌 (HCC) 具有广泛的腹膜传播方面表现出显著的有效性,即使在免疫治疗失败后也是如此. 这种氨酸激酶抑制剂在一个具有挑战性的患者病例中改善了症状并保持了疾病稳定性.
科学领域:
- 肝胆道医学 肝胆道医学
- 在瘤学瘤学.
- 翻译研究是翻译研究.
背景情况:
- 肝细胞癌 (HCC) 具有广泛的腹膜扩散呈现出不良预后和对全身疗法的耐药性.
- 恶性炎和胸腔溢液是常见的并发症,需要进行侵入性治疗.
- 目前,患有腹膜扩散的晚期HCC的治疗选择有限.
研究的目的:
- 报告一个晚期的HCC病例与巨大的腹膜扩散.
- 在联合免疫疗法失败后评估伦瓦提尼布的疗效.
- 突出林瓦提尼布在疾病稳定和症状改善中的作用.
主要方法:
- 一名47岁的女性患者患有HCC和腹传播被治疗.
- 最初的治疗包括联合免疫疗法 (杜尔瓦卢马布/特雷梅利卢马布).
- 随着疾病的进展,随后使用伦瓦提尼布进行了后续治疗.
主要成果:
- 伦瓦提尼布治疗导致CT成像中主要肝病变的动脉增强完全消失.
- 观察到腹膜扩散结节的大小显著减少.
- 在使用伦瓦提尼布的13个月内,疾病保持稳定,阿尔法-胎蛋白水平下降和症状改善.
结论:
- 伦瓦提尼布可以在患有晚期HCC和广泛的腹传播的患者中实现疾病稳定和症状改善.
- 这一案例表明伦瓦提尼布作为耐火性HCC与高瘤负担的潜在治疗选择.
- 需要进一步研究伦瓦提尼布在这种特定患者群体中的疗效.
相关概念视频
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K


